Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration

Haematologica

Volumn 99, Issue 7, 2014, Pages 1264-1271

  Bussel, James B ^a   Lee, Christina S ^a   Seery, Caroline ^a   Imahiyerobo, Allison A ^a   Thompson, Michaela V ^a   Catellier, Diane ^b   Turenne, Ithamar G ^a   Patel, Vivek L ^a,c   Basciano, Paul A ^a   Elstrom, Rebecca L ^a,d   Ghanima, Waleed ^a,e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b RTI INTERNATIONAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d GENENTECH INC   (United States)

^e Østfold Hospital Trust   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADOLESCENT; ADULT; ARTICLE; BEHAVIOR DISORDER; BONE PAIN; CHILD; CLINICAL TRIAL; COLITIS; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; GENOTYPING TECHNIQUE; HEADACHE; HUMAN; IMMUNE THROMBOCYTOPENIA; IMMUNOGLOBULIN DEFICIENCY; INDIGESTION; INFECTION; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PNEUMONIA; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SERUM SICKNESS; SINGLE NUCLEOTIDE POLYMORPHISM; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; INFANT; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; SPLENECTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903579618     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.103291     Document Type: Article

References (34)

1. Cines DB, McMillan R. Pathogenesis of chronic immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14(5):511-4.
2. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887-95.
3. Olson B, Andersson PO, Jernås M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cellmediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-4.
4. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2):168-86.
5. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9): 2549-54.
6. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood. 1984; 64(6):1179-83.
7. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012;120(5):960-9.
8. Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan P, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349(9):831-6.
9. Naithani R, Mahapatra M, Kumar R, Pravas M, Saxena R. High dose dexamethasone therapy shows better response in acute immune thrombocytopenia than in chronic immune thrombocytopenia. Platelets. 2010;21(4):270-3.
10. Borst F, Keuning J, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first-and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004;83(12):764-8.
11. Stasi R, Brunetti M, Pagano A, Stipa E, Masi M, Amadori S. Pulsed intravenous highdose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis. 2000;26(6):582-6.
12. Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109(4):1401-7.
13. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol. 2010;47(2):170-9.
14. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125 (2):232-9.
15. Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, et al. Long-term followup analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol. 2012;87(9):886-9.
16. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25-33.
17. Patel VL, Mahevas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, et al. Outcome at 5 years following response to rituximab therapy in children and adults with immune thrombocytopenia (ITP). Blood. 2012;119(25):5989-95.
18. Hasan A, Michel M, Patel V, Stasi R, Cunningham-Rundles S, Leonard JP, et al. Repeated courses of rituximab in chronic ITP: Three different regimens. Am J Hematol. 2009;84(10):661-5.
19. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115(14):2755-62.
20. Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013;121(11):1976-81.
21. Barsam SJ, Psaila B, Forestier M, Page LK, Sloane PA, Geyer JT, et al. Platelet production and platelet destruction: assessing mechanisms of effect in immune thrombocytopenia. Blood. 2011;117(21):5723-32.
22. Basciano PA, Bussel JB, Hafeez Z, Christos PJ, Giannakakou P. The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP). Br J Haematol. 2013;160(2):237-43.
23. Freson K, De Vos R, Wittevrongel C, Thys C, Defoor J, Vanhees L, et al. The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure. Blood. 2005;106(7):2356-62.
24. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121(23):4782-90.
25. Rodeghiero F, Ruggeri M. Is Splenectomy still the gold standard for the treatment of ITP? Am J Hematol. 2008;83(2):91.
26. Figueroa M, Gehlsen J, Hammond D, Ondreyco S, Piro L, Pomeroy T, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med. 1993;328(17):1226-9.
27. McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med. 2001; 344(18):1402-3.
28. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmue thrombocytopenic purpura. Blood. 1995;85(2):351-8.
29. Cheng Y, Wong R, Soo Y, Chui CH, Cheng G. Chan NP, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349(9):831-6.
30. Kojouri K, Vesely S, Terrell D, George J. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623-34.
31. Vianelli N, Palandri F, Polverelli N, Rodeghiero F, Joelsson J, Johansson E, et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 2013;98(6):875-80.
32. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107(7):2639-42.
33. Arnold DM, Nazi I, Santos A, Chan H, Heddle NM, Warkentin TE, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010;115(1):29-31.
34. Gomez-Almaguer D, Solano-Genesta M, Tarin-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116(23):4783-5.